AbbVie, DISCO Strike Up-to-$2.54B Cancer Deal
AbbVie and DISCO Pharmaceuticals have agreed to collaborate on discovering and developing AND-gated bispecific therapies for solid tumors, using DISCO’s platform to identify pairs of cancer-cell surface targets. The approach is designed to activate treatments only when both targets are present, potentially improving tumor selectivity and sparing healthy tissue. DISCO will receive $40 million upfront and could earn up to $2.5 billion in option, development and other milestone payments, plus tiered royalties; AbbVie may choose to license selected programs after research work is completed.



